Cargando…

Mixed states vs. pure mania in the french sample of the EMBLEM study: results at baseline and 24 months – European mania in bipolar longitudinal evaluation of medication

BACKGROUND: To describe the clinical course and treatment patterns over 24 months of patients experiencing an acute manic/mixed episode within the standard course of care. METHODS: EMBLEM was a 2-year European prospective, observational study on outcomes of patients experiencing a manic/mixed episod...

Descripción completa

Detalles Bibliográficos
Autores principales: Azorin, Jean-Michel, Aubrun, Elodie, Bertsch, Jordan, Reed, Catherine, Gerard, Stephanie, Lukasiewicz, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701946/
https://www.ncbi.nlm.nih.gov/pubmed/19500417
http://dx.doi.org/10.1186/1471-244X-9-33
_version_ 1782168723679870976
author Azorin, Jean-Michel
Aubrun, Elodie
Bertsch, Jordan
Reed, Catherine
Gerard, Stephanie
Lukasiewicz, Michael
author_facet Azorin, Jean-Michel
Aubrun, Elodie
Bertsch, Jordan
Reed, Catherine
Gerard, Stephanie
Lukasiewicz, Michael
author_sort Azorin, Jean-Michel
collection PubMed
description BACKGROUND: To describe the clinical course and treatment patterns over 24 months of patients experiencing an acute manic/mixed episode within the standard course of care. METHODS: EMBLEM was a 2-year European prospective, observational study on outcomes of patients experiencing a manic/mixed episode. Adults with bipolar disorder were enrolled within the standard course of care as in/outpatients if they initiated or changed oral medication for treatment of acute mania. After completing 12 weeks of acute phase, patients were assessed every 3–6 months during the maintenance phase. We present the 24 month results, with subgroup analysis for mixed states (MS) and pure mania (PM). These subgroup analyses are driven by the high proportion of antidepressants prescribed in this cohort. RESULTS: In France, 771 patients were eligible for the maintenance phase. 69% of patients completed the follow up over 24 months. The mean age was 45.5 years (sd = 13.6) with 57% of women. 504 (66%) patients were experiencing a PM and 262 (34%) a MS at baseline. The main significant differences in MS vs. PM at baseline were: a higher rate of women, and in the previous 12 months, a higher frequency of episodes (manic/mixed and depressive), more suicide attempts, more rapid cycling, fewer social activities and more work impairment. Over the 24 months of follow-up the MS group had a significantly lower recovery than PM (36% vs. 46%, p = 0.006). Overall, 42% of all patients were started on monotherapy and 58% on combination therapy; of those 35% and 30% respectively remained on their initial medication throughout the 24 months. At baseline, 36% were treated with an antidepressant, this proportion remains high throughout the follow-up period, with a significantly higher rate for MS vs. PM at 24 months (55% vs. 27%, p < 0.001). CONCLUSION: In this large sample, MS occur frequently (34%), they are more severe at baseline and have a worse functional prognosis than PM. Although antidepressants are not recommended in MS and PM, they were frequently prescribed at baseline and are maintained during the 24 months of follow-up.
format Text
id pubmed-2701946
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27019462009-06-26 Mixed states vs. pure mania in the french sample of the EMBLEM study: results at baseline and 24 months – European mania in bipolar longitudinal evaluation of medication Azorin, Jean-Michel Aubrun, Elodie Bertsch, Jordan Reed, Catherine Gerard, Stephanie Lukasiewicz, Michael BMC Psychiatry Research Article BACKGROUND: To describe the clinical course and treatment patterns over 24 months of patients experiencing an acute manic/mixed episode within the standard course of care. METHODS: EMBLEM was a 2-year European prospective, observational study on outcomes of patients experiencing a manic/mixed episode. Adults with bipolar disorder were enrolled within the standard course of care as in/outpatients if they initiated or changed oral medication for treatment of acute mania. After completing 12 weeks of acute phase, patients were assessed every 3–6 months during the maintenance phase. We present the 24 month results, with subgroup analysis for mixed states (MS) and pure mania (PM). These subgroup analyses are driven by the high proportion of antidepressants prescribed in this cohort. RESULTS: In France, 771 patients were eligible for the maintenance phase. 69% of patients completed the follow up over 24 months. The mean age was 45.5 years (sd = 13.6) with 57% of women. 504 (66%) patients were experiencing a PM and 262 (34%) a MS at baseline. The main significant differences in MS vs. PM at baseline were: a higher rate of women, and in the previous 12 months, a higher frequency of episodes (manic/mixed and depressive), more suicide attempts, more rapid cycling, fewer social activities and more work impairment. Over the 24 months of follow-up the MS group had a significantly lower recovery than PM (36% vs. 46%, p = 0.006). Overall, 42% of all patients were started on monotherapy and 58% on combination therapy; of those 35% and 30% respectively remained on their initial medication throughout the 24 months. At baseline, 36% were treated with an antidepressant, this proportion remains high throughout the follow-up period, with a significantly higher rate for MS vs. PM at 24 months (55% vs. 27%, p < 0.001). CONCLUSION: In this large sample, MS occur frequently (34%), they are more severe at baseline and have a worse functional prognosis than PM. Although antidepressants are not recommended in MS and PM, they were frequently prescribed at baseline and are maintained during the 24 months of follow-up. BioMed Central 2009-06-07 /pmc/articles/PMC2701946/ /pubmed/19500417 http://dx.doi.org/10.1186/1471-244X-9-33 Text en Copyright © 2009 Azorin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Azorin, Jean-Michel
Aubrun, Elodie
Bertsch, Jordan
Reed, Catherine
Gerard, Stephanie
Lukasiewicz, Michael
Mixed states vs. pure mania in the french sample of the EMBLEM study: results at baseline and 24 months – European mania in bipolar longitudinal evaluation of medication
title Mixed states vs. pure mania in the french sample of the EMBLEM study: results at baseline and 24 months – European mania in bipolar longitudinal evaluation of medication
title_full Mixed states vs. pure mania in the french sample of the EMBLEM study: results at baseline and 24 months – European mania in bipolar longitudinal evaluation of medication
title_fullStr Mixed states vs. pure mania in the french sample of the EMBLEM study: results at baseline and 24 months – European mania in bipolar longitudinal evaluation of medication
title_full_unstemmed Mixed states vs. pure mania in the french sample of the EMBLEM study: results at baseline and 24 months – European mania in bipolar longitudinal evaluation of medication
title_short Mixed states vs. pure mania in the french sample of the EMBLEM study: results at baseline and 24 months – European mania in bipolar longitudinal evaluation of medication
title_sort mixed states vs. pure mania in the french sample of the emblem study: results at baseline and 24 months – european mania in bipolar longitudinal evaluation of medication
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701946/
https://www.ncbi.nlm.nih.gov/pubmed/19500417
http://dx.doi.org/10.1186/1471-244X-9-33
work_keys_str_mv AT azorinjeanmichel mixedstatesvspuremaniainthefrenchsampleoftheemblemstudyresultsatbaselineand24monthseuropeanmaniainbipolarlongitudinalevaluationofmedication
AT aubrunelodie mixedstatesvspuremaniainthefrenchsampleoftheemblemstudyresultsatbaselineand24monthseuropeanmaniainbipolarlongitudinalevaluationofmedication
AT bertschjordan mixedstatesvspuremaniainthefrenchsampleoftheemblemstudyresultsatbaselineand24monthseuropeanmaniainbipolarlongitudinalevaluationofmedication
AT reedcatherine mixedstatesvspuremaniainthefrenchsampleoftheemblemstudyresultsatbaselineand24monthseuropeanmaniainbipolarlongitudinalevaluationofmedication
AT gerardstephanie mixedstatesvspuremaniainthefrenchsampleoftheemblemstudyresultsatbaselineand24monthseuropeanmaniainbipolarlongitudinalevaluationofmedication
AT lukasiewiczmichael mixedstatesvspuremaniainthefrenchsampleoftheemblemstudyresultsatbaselineand24monthseuropeanmaniainbipolarlongitudinalevaluationofmedication